Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer
Gaopeng Li,Guoliang Wang,Fenqing Chi,Yuqi Jia,Xi Wang,Quankai Mu,Keru Qin,Xiaoxia Zhu,Jing Pang,Baixue Xu,Guangen Feng,Yuhu Niu,Tao Gong,Hongwei Zhang,Xiushan Dong,Ting Liu,Jinfeng Ma,Zefeng Gao,Kai Tao,Feng Li,Jun Xu,Baofeng Yu
DOI: https://doi.org/10.1136/jitc-2020-002218
IF: 12.469
2021-03-01
Journal for ImmunoTherapy of Cancer
Abstract:Background The satisfactory prognostic indicator of gastric cancer (GC) patients after surgery is still lacking. Perioperative plasma extracellular vesicular programmed cell death ligand-1 (ePD-L1) has been demonstrated as a potential prognosis biomarker in many types of cancers. The prognostic value of postoperative plasma ePD-L1 has not been characterized. Methods We evaluated the prognostic value of preoperative, postoperative and change in plasma ePD-L1, as well as plasma soluble PD-L1, in short-term survival of GC patients after surgery. The Kaplan-Meier survival model and Cox proportional hazards models for both univariate and multivariate analyzes were used. And the comparison between postoperative ePD-L1 and conventional serum biomarkers (carcinoembryonic antigen (CEA), cancer antigen 19–9 (CA19-9) and CA72-4) in prognostic of GC patients was made. Results The prognostic value of postoperative ePD-L1 is superior to that of preoperative ePD-L1 on GC patients after resection, and also superior to that of conventional serum biomarkers (CEA, CA19-9 and CA72-4). The levels of postoperative ePD-L1 and ePD-L1 change are independent prognostic factors for overall survival and recurrence free survival of GC patients. High plasma level of postoperative ePD-L1 correlates significantly with poor survival, while high change in ePD-L1 level brings the significant survival benefit. Conclusions The level of plasma postoperative ePD-L1 could be considered as a candidate prognostic biomarker of GC patients after resection.
oncology,immunology